Dr Zhou Huijun graduated from Wuhan University with a bachelor's degree, and then went to the United States to study. He received his Ph.D. in molecular biology and genetics from Cornell University and completed his postdoctoral research in clinical molecular genetics from Stanford University. Finally, he was certified as a clinical molecular geneticist by the American Medical Genetics Committee and a member of the American Medical Genetics Society. He is the only 323 certified clinical molecular geneticist in the world by the American Society of Medical Genetics (ABMG), which is a rare achievement for scientists who have studied in the United States and become recognized geneticists, and it is also rare in the field of Chinese scientists.

Personalized medical treatment through genes is a new field of biogenetics, and Dr. Zhou Huijun has been engaged in industrial and scientific research in this field for more than 14 years. From 65438 to 0998-2002, Dr. Zhou Huijun led the biogenetics project of Incyte Genomics. As the head of pharmacogenetics in this company, she helps pharmaceutical companies with drug research and development and services, including clinical drug trial design. Since then, Dr. Zhou Huijun has been the senior director of DNA Direct, a Silicon Valley company. DNA Direct mainly provides DNA testing and online medical genetics services, promotes medical services guided by personal genetic maps, helps prevent diseases, improves the quality of life, and realizes personalized treatment.

At the end of 2008, Dr. Zhou Huijun led his core team back to China to start a business, and formally established iDNA (Yiji Biotechnology) in Beijing, becoming the first Internet gene information service platform in China. At the same time, he was invited to join Yajie Chamber of Commerce and officially became the president of Baihuahui Beijing Branch, the world's top Chinese biogenetics association. Before returning to China, iDNA's core bio-gene technology and business model won the first place in the evaluation of American biomedical business plan in early 2008 and the second place in Beijing Innovation China Project Exhibition in 2009. In cooperation with the Chinese Center for Disease Control, it has carried out research projects on genes and health in seven cities including Beijing, Wuhan, Chengdu, Qingdao, Hangzhou, Harbin and Kunming. In 2009, he participated in the research on major special topics of the national science and technology platform of the Ministry of Science and Technology.